Sign in
Taking people in United StatesPhase 2/3

Galantamine for metabolic syndrome in people with long-term spinal cord injury

Tests galantamine for metabolic syndrome in adults living with long-term spinal cord injury.

Key facts

Who runs it
Northwell Health
Where
Manhasset, The Bronx, and West Orange, United StatesSee the 3 sites
Trial code
Registry title
Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
Status
Recruiting
Phase
Phase 2/3
People taking part
60 people, planned
Started
15 Oct 2026
Expected to end
Dec 2027
Type of study
Interventional
Treatments tested
  • Galantamine Hydrobromide Extended Release
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a long-standing spinal cord injury caused by trauma who also have metabolic syndrome. Metabolic syndrome is a group of problems such as belly fat, high blood sugar and abnormal blood fats.

Age
21 to 75 years
Sex
Male or female
Disease stage
Traumatic spinal cord injury that is not getting worse, at least 1 year since the injury. Tetraplegia (neck level) or paraplegia (any level). Uses a wheelchair to get around in the community. Metabolic syndrome means at least 3 of: waist ≥94 cm (37 in), fasting glucose ≥100 mg/dL (5.6 mmol/L), triglycerides ≥150 mg/dL (1.7 mmol/L) or HDL cholesterol <40 mg/dL (1 mmol/L) for men and <50 mg/dL (1.3 mmol/L) for women, CRP >1 mg/dL (0 mmol/L). Waist must be ≥94 cm (37 in).
Biomarker or test result
Resting heart rate above 45 bpm. Heart tracing (12-lead ECG) without important heart problems. Bowel function score below 10 on the ISCI-BDS.

Main reasons for not taking part

  • Other nerve injury or condition besides spinal cord injury, or a condition that is getting worse
  • Heart disease, irregular heartbeat or resting heart rate below 45 bpm
  • Pregnant, planning pregnancy or breastfeeding
  • Active cancer or current cancer treatment
  • Triglycerides ≥400 mg/dL (4.5 mmol/L), or regular use of medicines that interact with galantamine

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Adults aged 21-75 years (male or female)
  • Chronic (≥1 year post injury) traumatic non-progressive spinal cord injury (SCI)
  • Wheelchair user for community mobility
  • Injury level of tetraplegia (cervical level) or paraplegia (all levels)
  • SCI-specific obesity indicated by waist circumference ≥94 cm
  • Resting heart rate >45 bpm based on 10 measurements over 10 minutes
  • Without clinically significant cardiovascular abnormalities as indicated by 12-lead ECG
  • Tolerable bowel routine indicated by a score of <10 on the International SCI Bowel Function Data Set (ISCI-BDS)
  • Metabolic Syndrome (MetS) defined by the presence of at least three of the following: (1) obesity indicated by SCI-specific waist circumference ≥94 cm, (2) elevated fasting glucose ≥100 mg/dL, (3) dyslipidemia: high triglycerides ≥150 mg/dL or low HDL cholesterol <40 mg/dL for men and <50 mg/dL for women, (4) C-reactive protein (CRP) levels >1 mg/dL
  • Able to understand and communicate in English at the level of describing adverse event frequency and severity and completing validated outcome measures
  • Willingness to comply with all study procedures and availability for the duration of the study
  • Provision of signed and dated informed consent form

Who cannot take part

  • Severe concurrent medical disease, condition, or illness judged to be contraindicated by the site physician
  • Chronic use of medications with known or probable interactions with galantamine
  • Diagnosis of neurological injury or condition other than SCI
  • Progressive condition that would be expected to change neurological status
  • Signs and symptoms of cardiovascular disease or cardiac arrhythmias
  • Resting heart rate <45 bpm
  • Active cancer or currently in treatment for cancer
  • Triglyceride levels ≥400 mg/dL
  • Score of 10 or greater on the ISCI-BDS v2.1 indicating moderate to severe neurogenic bowel dysfunction
  • Psychopathology documented in the medical record or history that may conflict with study objectives
  • Pregnancy (participant reported or determined by clinical lab test), women who plan to become pregnant, or women who are nursing during the study
  • Enrolled in another research study that is likely to interfere with conduct or results of the current study
  • Any other reason the site physician feels that participation is contraindicated

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 75 years old?

Where in United States

  • Northwell HealthManhasset, United StatesContact: Welmi Pello, MPH, RNTaking people
  • James J Peters VA Medical CenterThe Bronx, United StatesContact: Dylan Arnero, MATaking people
  • Kessler Institute for RehabilitationWest Orange, United StatesContact: Trevor Dyson-Hudson, MDNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.

The group in the trial

  • Galantamine ERTreatment being tested

    All participants (tetraplegia and paraplegia cohorts) receive galantamine hydrobromide extended release (ER) capsules. Aim 1 (Day 1): single 8mg dose administered orally in the laboratory with at least 5 hours of monitored observation. Aim 2 (Weeks 1-12): 8mg once daily for Weeks 1-4, with dose escalation to 16mg (two 8mg capsules) once daily for Weeks 5-12 based on tolerability. Taken orally in the morning with a meal. The two cohorts (tetraplegia and paraplegia) are analyzed separately as pre-specified subgroups.

    Treatment: Galantamine Hydrobromide Extended Release

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Pilot Study of Tolerability and Preliminary Efficacy of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
Plain-language title
Galantamine for metabolic syndrome in people with long-term spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07625332, who can take part
Record updated
4 November 2026